Total Funding
51
73
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
29379
Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.
Xia Yu: CEO & ChairmanPast Role: Crown Bioscience, Sr Vice President
Li Baiyong: CSOPast Role: Pfizer, Associate Director
About the Company
The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line.
The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R &
D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner.
